Re: GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines
Thank you Professor Treweek for responding to my comment. Perhaps, what you are saying is that our best estimate is that compared with warfarin, dabigatran will “probably” result in 8 fewer deaths per 1000 patients; however, our findings are compatible with the possibility that that there might be no (additional) risk reduction. Would this be a fair statement to make?
Competing interests: No competing interests